MINI FUTURE OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 15:51:52 2024-05-17 EDT | ||
| 11.26 EUR | -3.68% |
|
| Current month | -30.92% | ||
| 1 month | -31.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 11.26 | -3.68% |
| 24-05-16 | 11.69 | -3.15% |
| 24-05-15 | 12.07 | -6.72% |
| 24-05-14 | 12.94 | +1.09% |
| 24-05-13 | 12.8 | -5.33% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 03:51 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB39CC |
| ISIN | DE000JB39CC4 |
| Date issued | 2023-10-17 |
| Strike | 567.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 18.55 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.67 € |
|---|---|
| Lowest since issue | 11.13 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
445.2
USD
Average target price
462.6
USD
Spread / Average Target
+3.90%
- Stock Market
- Certificates
- Certificat